IMUXImmunic Inc
IMUX
Immunic Inc12,607
Mkt Cap
$108.05MVolume
662,459.0052W High
$1.3552W Low
$0.5062PE Ratio
-1.04IMUX Fundamentals
Price
$0.8916Prev Close
$0.8983Open
$0.88150D MA
$0.6738Beta
1.49Avg. Volume
1.59MEPS (Annual)
-$1.00P/B
8.44Rev/Employee
$0.00$65.51
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday
Immunic (NASDAQ:IMUX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·6d ago
Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic Announces Closing of Oversubscribed Private Placement Financing Immunic Announces Closing of Oversubscribed Private Placement Financing PR Newswire NEW YORK, Feb. 17, 2026 Upfront Proceeds of...
PR Newswire·8d ago
Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push
In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.Shares of Immunic, Inc. (Nasdaq: IMUX) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for ...
AllPennyStocks.com·12d ago
Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push
In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.Shares of Immunic, Inc. (Nasdaq: IMUX) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for ...
AllPennyStocks.com·12d ago
D. Boral Capital Lowers Immunic (NASDAQ:IMUX) Price Target to $4.00
D. Boral Capital cut their price target on shares of Immunic from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Friday...
MarketBeat·12d ago
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company Immunic Announces Oversubscribed Private Placement of up to USD...
PR Newswire·12d ago
HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)
HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Immunic in a research report on Monday...
MarketBeat·16d ago
Brookline Cap M Predicts Immunic FY2025 Earnings
Immunic, Inc. (NASDAQ:IMUX - Free Report) - Brookline Cap M issued their FY2025 EPS estimates for shares of Immunic in a research note issued to investors on Tuesday, February 3rd. Brookline Cap M...
MarketBeat·19d ago
Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M
Brookline Cap M raised shares of Immunic to a "strong-buy" rating in a research note on Tuesday...
MarketBeat·19d ago
<
1
2
...
>